CSL Behring recently celebrated five scientists who have received grants through the 2022 Heimburger Award, named for Professor Norbert Heimburger, a former CSL Behring researcher and pioneer of modern coagulation therapy.
For more than a decade, CSL Behring has supported the award program as part of its commitment to inspiring the next generation of coagulation specialists and supporting novel research of hematological disorders. CSL Behring is a global biotech company that specializes in treatments for rare diseases, including hemophilia and other bleeding disorders.
The winners, who will receive grants totaling €125,000 ($133,000 US), are:
•Romein Dujardin, MD – Amsterdam University Medical Centers, The Netherlands
Research topic: Role of fibrinogen in disseminated intravascular coagulation
•Ellie Karampini, PhD – Royal College of Surgeons in Ireland (RCSI), Ireland
Research topic: Terminal sialylation as a novel regulator of VWF biosynthesis and intracellular trafficking in endothelial cells
•Emma Leitinger, MBBS, BMedSci – Monash Health, Australia.
Research topic: Comparability of anti-Xa assessments using alternate calibration curves in patients receiving rivaroxaban and apixaban therapy
•Chiara Suffritti, PhD – Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Italy
Research topic: Phenotypic variability in hemophilia: role of miRNAs
•Claudia Tersteeg, PhD – KU Leuven Campus Kulak Kortrijk, Belgium
Research topic: Mitochondrial regulation of procoagulant platelet formation
“As a leader in the development of innovative therapies that support those living with bleeding disorders, we are driven by our promise to patients. We understand the vital importance of research advancements,” said Debbie Drane, CSL Behring’s Senior Vice President of Commercial Development. “Through our support of the Professor Heimburger Award, we are proud to champion the next generation of coagulation specialists as they further establish their research and continue to progress innovation in this therapeutic area.”
